RxDoctor Payments Data

Amber Wood, MD

Child & Adolescent Psychiatry · Lexington, KYNPI 1750878039

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.7% of the total across 188 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 25.4% of the total. Among child & adolescent psychiatry clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,406in general payments, 2019–2025

Across 188 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$864
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$538
  • Teva Pharmaceuticals USA, Inc.$469
  • Axsome Therapeutics, Inc.$221
  • Johnson & Johnson$190
  • Otsuka America Pharmaceutical, Inc.$152
  • plus $970 from 12 others

What the payments were for

  • Food & beverage$3,29497%
  • Education$1113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,406 in reported general payments places this provider in the 90th percentile of 43 child & adolescent psychiatry providers in Kentucky.

See all child & adolescent psychiatry providers in Kentucky

Medicare billing

Part B allowed, 2024
$13,320
Medicare patients
35
Services billed
159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl21$37,715
RexultiBrexpiprazole18$26,819
Lurasidone Hcl35$8,530
Paliperidone ErPaliperidone11$5,746
Buspirone Hcl37$681
Sertraline Hcl42$566
Duloxetine Hcl23$421
Lamotrigine50$391
Hydroxyzine Hcl40$380
Bupropion XlBupropion Hcl18$356
Mirtazapine29$344
Quetiapine Fumarate37$341
Trazodone Hcl22$338
Propranolol Hcl25$314
Fluoxetine Hcl16$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$864$37,71521 claims
Otsuka America Pharmaceutical, Inc.Rexulti$152$26,81918 claims
Almatica Pharma LLCSertraline Hcl$23$56642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 43 child & adolescent psychiatry providers in Kentucky.

Other child & adolescent psychiatry in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →